Fujiwara, Kenji
Shao, Yingkuan
Niu, Nan
Zhang, Tengyi
Herbst, Brian
Henderson, Mackenzie
Muth, Stephen
Zhang, Pingbo
Zheng, Lei
Funding for this research was provided by:
Japan Society for the Promotion of Science (Overseas Research Fellowship)
National Institutes of Health (R01 CA169702)
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
Article History
Received: 18 July 2022
Accepted: 11 October 2022
First Online: 25 October 2022
Declarations
:
: Human PDAC resection specimens were obtained from the patients who underwent surgery at the Johns Hopkins Hospital under the Johns Hopkins Medical Institution (JHMI) Institutional Review Board (IRB) approved protocol (IRB00244430) which allows the access of de-identified tumor specimens and PBMCs archived from clinical trial participants who consented for using their specimens for other researches.
: Not applicable.
: LZ receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. LZ is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, QED, Xilio, Novagenesis, Snow Lake Capitals, Amberstone, Tavotek Lab, and Mingruizhiyao. LZ holds shares at Alphamab and Mingruizhiyao. No potential conflicts of interest were disclosed by the other authors.